TY - JOUR
T1 - Fe3+-DOX-mediated self-assembled nanolipids for tumor microenvironment activated synergistic ferroptotic-chemo therapy assisted with MR-imaging
AU - Cao, Changyu
AU - Si, Guangxiang
AU - Yang, Nan
AU - Wang, Wenjun
AU - Zhang, Zheye
AU - Zang, Fengchao
AU - Song, Xuejiao
AU - Chen, Peng
AU - Dong, Xiaochen
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/9/15
Y1 - 2024/9/15
N2 - Chemotherapy is often plagued by side-effects, development of drug resistance, difficulty of targeted delivery, and limited effectiveness. Here, we tackle these issues by rationally designing a nanolipid system with the capabilities of selective accumulation in tumor tissues, responsiveness to tumor microenvironment (TME), synergistic combination of chemotherapy with ferroptosis, magnetic resonance (MR) imaging to monitor the uptake kinetics and therapeutic process. Specifically, a tumor-responsive nanolipid encapsulated with Fe3+-DOX nanocomplexes is devised. DOX is only released inside the tumor cells and subsequently induces apoptosis after the nanolipids are selectively accumulated in tumor tissues, readily uptaken by tumor cells, and finally disassembled by overexpressed glutathione (GSH). Free Fe2+ ions reduced from Fe3+ by GSH catalyze the excess H2O2 in tumor cells into cytotoxic ·OH radicals, which in turn cause lipid peroxidation and consequently ferroptosis. Intracellularly released Fe3+-DOX nanocomplexes emit strong MR signal, indicating successful internalization of the therapeutics and initiation of the ferroptotic-chemotherapy. Such MR imaging-monitored, highly targeted, synergistic therapy offers high therapeutic efficacy, low side-effects, and immunity to drug resistance.
AB - Chemotherapy is often plagued by side-effects, development of drug resistance, difficulty of targeted delivery, and limited effectiveness. Here, we tackle these issues by rationally designing a nanolipid system with the capabilities of selective accumulation in tumor tissues, responsiveness to tumor microenvironment (TME), synergistic combination of chemotherapy with ferroptosis, magnetic resonance (MR) imaging to monitor the uptake kinetics and therapeutic process. Specifically, a tumor-responsive nanolipid encapsulated with Fe3+-DOX nanocomplexes is devised. DOX is only released inside the tumor cells and subsequently induces apoptosis after the nanolipids are selectively accumulated in tumor tissues, readily uptaken by tumor cells, and finally disassembled by overexpressed glutathione (GSH). Free Fe2+ ions reduced from Fe3+ by GSH catalyze the excess H2O2 in tumor cells into cytotoxic ·OH radicals, which in turn cause lipid peroxidation and consequently ferroptosis. Intracellularly released Fe3+-DOX nanocomplexes emit strong MR signal, indicating successful internalization of the therapeutics and initiation of the ferroptotic-chemotherapy. Such MR imaging-monitored, highly targeted, synergistic therapy offers high therapeutic efficacy, low side-effects, and immunity to drug resistance.
KW - Chemotherapy
KW - Ferroptosis
KW - Magnetic resonance imaging
KW - Tumor-responsive nanolipids
UR - http://www.scopus.com/inward/record.url?scp=85194104208&partnerID=8YFLogxK
U2 - 10.1016/j.snb.2024.136039
DO - 10.1016/j.snb.2024.136039
M3 - 文章
AN - SCOPUS:85194104208
SN - 0925-4005
VL - 415
JO - Sensors and Actuators B: Chemical
JF - Sensors and Actuators B: Chemical
M1 - 136039
ER -